Montarioso

Philogen enters into a Service and Supply Agreement with IBSA for the GMP Production of a Therapeutic Protein

Retrieved on: 
Wednesday, June 28, 2023
GMP, CSO, IBSA, BIT, Country, Plant, Investment, Vaccine, Fine chemical, Montarioso, Jaden Philogene

Siena, Italy, 28thJune 2023 – Philogen S.p.A (BIT: PHIL) today announced that it has entered into a Service and Supply Agreement with IBSA (Institut Biochimique SA) to produce a recombinant therapeutic protein at Philogen GMP Facilities in Siena (Italy).

Key Points: 
  • Siena, Italy, 28thJune 2023 – Philogen S.p.A (BIT: PHIL) today announced that it has entered into a Service and Supply Agreement with IBSA (Institut Biochimique SA) to produce a recombinant therapeutic protein at Philogen GMP Facilities in Siena (Italy).
  • Philogen owns a GMP production facility in Montarioso (Siena, Italy) which is authorized and operational for the manufacturing of investigational therapeutic proteins in mammalian cells.
  • The facility has been formally certified by AIFA since 2004 and is subject to strict regulatory and manufacturing requirements.
  • Philogen uses its production facilities both to manufacture its own proprietary products and to run GMP lots for third parties.

Board of Directors Approves Half-Year Financial Report as of June 30, 2022

Retrieved on: 
Wednesday, September 28, 2022
Financial statement, IFRS, Phase, Jaden Philogene-Bidace, Contract, Company, Treasury, Genta (company), Compliance, Doxorubicin, Intellectual property, Legislature, Melanoma, Industry, Business, Glioblastoma, Book, Program, Patient, Clinical trial, Investment, Cancer, Ligand, AIFA, Finance, Blood, Share repurchase, Report, Antigen, Board of directors, Tissue, Method, Press release, Board, Lomustine, Research, Marketing, Business development, HIV disease progression rates, GMP, DNA-encoded chemical library, Disease, Mission statement, Renewable energy, Pharmaceutical industry, Medical imaging, Vaccine, Audit, Group, Montarioso

In the same period, liquidity increased from 92,593 thousand as of March 31, 2022 to 98,339 thousand as of June 30, 2022, showing an increase of approximately 6.2%.

Key Points: 
  • In the same period, liquidity increased from 92,593 thousand as of March 31, 2022 to 98,339 thousand as of June 30, 2022, showing an increase of approximately 6.2%.
  • Current and non-current financial debt decreased from 16,248 thousand as of March 31, 2022, to 16,225 thousand as of June 30, 2022, showing a decrease of approximately 0.14% resulting from the progress of existing amortization schedules.
  • Opening of new centers in Germany, Spain, Italy and Poland for the European Phase III study of first-line soft tissue sarcoma.
  • The Board of Directors approved the Group Sustainability Brochure, referring to the year 2021, which will be published on the Company's website ( https://www.philogen.com) in the "Governance" section.